FDA Inspection 1274472 — AbbVie Deutschland GmbH & Co. KG

AbbVie Deutschland GmbH & Co. KG — FEI 3002807401

The FDA completed an inspection of AbbVie Deutschland GmbH & Co. KG on September 28, 2023 in Ludwigshafen. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
September 28, 2023
Fiscal Year
2023
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Ludwigshafen (Germany)

Additional Details

Mutual Recognition Agreement (MRA)